AstraZeneca's Strategic U.S. Expansion Amid Price-Cutting Moves

AstraZeneca adjusts its U.S. strategy by proposing drug price cuts and expanding local production in response to pressure from President Trump. The company aims to balance pricing globally while boosting U.S. sales. With strong quarterly growth, AstraZeneca plans significant revenue growth by 2030 despite potential tariff challenges.


Devdiscourse News Desk | Updated: 29-07-2025 19:30 IST | Created: 29-07-2025 19:30 IST
AstraZeneca's Strategic U.S. Expansion Amid Price-Cutting Moves
This image is AI-generated and does not depict any real-life event or location. It is a fictional representation created for illustrative purposes only.

AstraZeneca is adapting its U.S. growth strategy, introducing drug price cuts amid pressure from President Trump's administration. The pharmaceutical giant seeks to balance global pricing while bolstering its American market presence.

CEO Pascal Soriot confirmed that all U.S. drugs would soon be locally produced. The company anticipates strong local demand to continue driving revenue growth, with recent quarterly profits exceeding expectations.

AstraZeneca's strategic moves come as the company navigates potential U.S. tariffs and direct sales strategies, aiming for an annual revenue target of $80 billion by 2030. Despite headwinds, its focus remains on expanding in the nation's vast healthcare market.

(With inputs from agencies.)

Give Feedback